Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Brain Cancer. 12 results shown below.

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

[Complete title: Benzylguanine Mediated Tumor Sensitization with Chemoprotected Autologous Stem Cells for Patients with Malignant Glioma]
Principal Investigator: Hans-Peter Kiem, MD
Study Number: 2000.00
Phase: I/II

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

[Complete title: Cellular Proliferation Imaging Using [18F]fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors]
Principal Investigator: Jason Rockhill
Study Number: 7754
Phase: NA

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

[Complete title: ACNS0332, Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0332
Phase: III

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors (SEED)

[Complete title: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients with Refractory or Recurrent Brain Tumors]
Principal Investigator: Sarah Leary
Study Number: SC-9006
Phase: Pilot

Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma

[Complete title: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma]
Principal Investigator: George Laramore, MD, PhD
Study Number: 8078
Phase: III

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

[Complete title: RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma]
Principal Investigator: George Laramore, MD, PhD
Study Number: 8024
Phase: II

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

[Complete title: Phase I Study of CDK 4-6 Inhibitor PD-0332991 In Children With Recurrent, Progressive or Refractory Central Nervous System Tumors]
Principal Investigator: Sarah Leary
Study Number: PBTC-042
Phase: I

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

[Complete title: Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children]
Principal Investigator: Sarah Leary
Study Number: PNOC001
Phase: II

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

[Complete title: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E-or BRAF Ins T mutant gliomas]
Principal Investigator: Sarah Leary
Study Number: PNOC002
Phase: Pilot

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7)

[Complete title: A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges]
Principal Investigator: Christina Baik
Study Number: 20150427
Phase: II

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

[Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements]
Principal Investigator: Gabriela Chiorean
Study Number: 20152369
Phase: II

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

[Complete title: SC-4003, Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V600-Mutation Positive Solid Tumors.]
Principal Investigator: Sarah Leary
Study Number: SC-4003
Phase: I/II

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials